Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic LeukemiaCommunication Published on 2021-09-232022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-Spike IgG antibody Antibody Response chronic chronic lymphocytic leukemia CLL COVID-19 COVID-19 vaccine dose Follow-up General population highlight IgG level Immunocompromised patients increase in kidney transplant kidney transplant recipient kidney transplant recipients leukemia longitudinal moderate mRNA patients treated Prevalence preventive measure PROTECT recipient response Retrospective study SARS-CoV-2 anti-spike IgG Transplant vaccination Vaccine [DOI] 10.3390/vaccines9101055 PMC 바로가기 [Article Type] Communication
COVID-19 vaccination immune response in patients with solid organ and haematologic malignancies: call for active monitoringShort Communication Published on 2021-09-072022-10-31 Journal: ecancermedicalscience [Category] COVID-19, [키워드] anti-Spike IgG approval center Chemotherapy clinical trial Community coronavirus 2 COVID-19 COVID-19 in patient COVID-19 vaccination demonstrated dose Efficacy General population greater haematologic highlight hospitalisation immune response immunocompromised individual Immunosuppressive treatment include Infection measure organ Patient Population Preliminary data Prospective Study receiving reduce reduced resource respiratory risk of COVID-19 SARS-CoV-2 seroconversion rates Therapies therapy Transmission university Vaccine [DOI] 10.3332/ecancer.2021.1284 PMC 바로가기 [Article Type] Short Communication
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial아데노바이러스 벡터화 및 mRNA COVID-19 백신(Com-COV)을 사용한 이종 대 상동 프라임-부스트 일정의 안전성 및 면역원성: 단일 맹검, 무작위, 비열등성 시험Clinical Trial Published on 2021-09-042022-09-11 Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, [키워드] (ChAdOx1 nCoV-19 Administered age anti-Spike IgG approved assigned AstraZeneca baseline blood test blood tests BNT BNT162b2 boost ChAd ChAdOx1 ChAdOx1 nCoV-19 Cohort Comorbidity comparison Concentration COVID-19 COVID-19 disease COVID-19 vaccine COVID-19 vaccines criteria dose Efficacy eight eligible eligible participant Eligible participants ELISA enrolled evaluate facilitate female participant force geometric mean geometric mean concentration geometric mean ratio GMR greater groups Heterologous heterologous prime-boost heterologous schedule heterologous schedules homologous homologous schedule hospitalisation immune immune responses immunisation immunogenicity immunology inferiority ISRCTN laboratory confirmation limit majority mRNA mRNA vaccine non-inferiority non-inferiority trial occurred Older participant per-protocol population Pfizer-BioNTech primary analysis primary endpoint prime-boost interval prime-boost intervals randomised Randomly reactogenic reactogenicity receive receiving recipient recruited referred to regimen Registered reported Safety safety analyses safety analysis SARS-CoV-2 anti-spike IgG SARS-COV-2 infection Serious Adverse Event seronegative serum single-blind subset Support Task Force the SARS-CoV-2 the vaccine These data Trial vaccination Vaccine Vaccines vectored vaccine was done [DOI] 10.1016/S0140-6736(21)01694-9 PMC 바로가기 [Article Type] Clinical Trial
Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab오크렐리주맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 mRNA 백신에 대한 체액 반응 둔화의 예비 증거Article Published on 2021-09-012022-09-11 Journal: Neurological Sciences [Category] MERS, SARS, 진단, 치료기술, [키워드] all subject all subjects Anti-spike anti-Spike IgG Antibody Units baseline BAU binding antibody units BNT162b2 Case series case sery collected COVID-19 COVID-19 infection develop DiaSorin disease expand first dose geometric geometric mean health-care healthy subject healthy subjects humoral Humoral response IgG antibodies IgG antibody immunogenicity Infection International international standard majority mounted mRNA mRNA vaccine Multiple multiple sclerosis Ocrelizumab patients treated preliminary evidence relapsing SARS-CoV-2 SARS-CoV-2 mRNA vaccine SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARSCoV-2 second dose second dose of vaccine sera serum sample serum samples Spike protein tested Therapies treated unit Vaccine were expressed [DOI] 10.1007/s10072-021-05397-7 PMC 바로가기 [Article Type] Article
Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort입원한 페루 COVID-19 코호트에서 더 나쁜 예후와 관련된 사이토카인 프로필Immunology Published on 2021-09-012022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 진단, [키워드] 95% confidence interval 95%CI activated adaptive analyses Analysis analyzed anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody concentration baseline Biomarker Biomarkers C-reactive protein chemokine chemokines clinical parameter Clinical parameters Cohort Concentration correlated COVID-19 COVID-19 patient creatinine criteria CRP cytokine Cytokines D-dimer D-dimer levels death determine died discharge disease severity e parameters ELISA enrolled evaluated exacerbated expression expression profile fatal COVID-19 form Frequency GM-CSF groups growth factor Growth factors hazard ratio hemoglobin hospital Hospitalization Hospitalized hospitalized COVID-19 patients identify IL-10 IL-12p70 IL-15 IL-5 IL-6 IL-8 IL1RA Immune cell immune cells Inflammation laboratory-confirmed Laboratory-confirmed COVID-19 Logistic regression longitudinal longitudinal analysis longitudinal samples lymphocyte Lymphocytes MCP-1 MIP-1α moderate disease Mortality multivariable analysis Neutrophils obesity outcome outcomes parameter Patient patient information patients with moderate Peripheral blood pro-inflammatory cytokines profile Prognosis proinflammatory Protein Quantitative Result risk factor SARS-CoV-2 IgG SARS-CoV-2 infected patient SARS-CoV-2 infected patients SARS-COV-2 infection sera severe disease severity Significant significant difference significant differences spike IgG Stratification TNFα worse prognosis [DOI] 10.3389/fimmu.2021.700921 PMC 바로가기 [Article Type] Immunology
Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case백신 혁신 SARS-CoV-2 입원 델타(B.1.617.2) 변종 사례에서 단일클론항체 치료Case Reports Published on 2021-09-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 24 hour 24 hours anti-Spike IgG B.1.617.2 bamlanivimab bamlanivimab/etesevimab breakthrough COVID-19 Delta delta variant etesevimab father father and son Hospitalization individuals monoclonal antibody monoclonal antibody therapy Older Patient resolved SARS-CoV-2 serum Symptom therapy Vaccine variant variant of concern [DOI] 10.1016/j.ijid.2021.07.029 PMC 바로가기 [Article Type] Case Reports
Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers의료 종사자에서 코로나백 2회 투여 후 SARS-CoV-2 스파이크 단백질에 대한 항체 정량Article Published on 2021-09-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] Abbott acute respiratory syndrome Adaptive immune response age Anti-spike anti-Spike IgG antibody Antibody titer Chemiluminescent microparticle immunoassay chronic disease Chronic diseases CoronaVac coronavirus cutoff value detection dose facilitate female first dose Frequency greater group HCW HCWs healthcare healthcare worker Healthcare workers help highest Humoral immunity immunoassay indicated less male median men Microparticle performed positive produced quantitation recruited reported Result SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 spike protein second dose Seropositivity serum sample significantly significantly higher the antibody response the spike protein the vaccine Turkey university hospital vaccination was performed women [DOI] 10.1002/jmv.27098 PMC 바로가기 [Article Type] Article
Seroconversion rates following COVID-19 vaccination among patients with cancer암환자의 코로나19 예방접종 후 혈청전환율Article Published on 2021-08-092022-09-12 Journal: Cancer cell [Category] MERS, SARS, 진단, [키워드] Affect anti-CD20 therapy anti-Spike IgG antibody Cancer Cohort COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccines demonstrated hematologi malignancies Hematologic malignancy hormonal therapy identify IgG titer immune immunization strategies Immunosuppressed immunosuppressive therapy inhibitor mRNA-based vaccines New York City oncology patient Patient Patients with cancer post vaccination prophylactic strategy rate of seroconversion receiving recipient SARS-CoV-2 spike protein Seroconversion seroconversion rate significantly lower solid tumor Stem cell transplantation therapy vaccination Vaccine [DOI] 10.1016/j.ccell.2021.06.002 PMC 바로가기 [Article Type] Article
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers개별 의료 종사자의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 항체 반응의 기간, 역학 및 결정인자Article Published on 2021-08-022022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료기술, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-Spike IgG anti-spike IgG levels antibody antibody half-life antibody levels Antibody Response Antibody responses Asian association Bayesian can be used Chain Reaction coronavirus coronavirus 2 COVID-19 credibility interval CrI detectable determinant Duration Dynamics estimate example faster future infection half-lives HCW HCWs healthcare worker IgG IgG level Immunity Immunoglobulin Immunoglobulin G Increasing increasing age individual interval Linear model longitudinal Longitudinal studies longitudinal study median nucleocapsid IgG polymerase chain polymerase chain reaction positive positive PCR test positive result Positive test proportion Reinfection remained required respiratory response responses risk SARS-CoV-2 self-reported symptom serology seropositive severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 survival survival analysis Symptom the mean was used were used without symptoms worker [DOI] 10.1093/cid/ciab004 PMC 바로가기 [Article Type] Article
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgGSARS-CoV-2에 대한 안티스파이크 IgG의 1년 내구성: 안티크라운 전향적 관찰 연구의 예비 데이터 COVID-19 안티스파이크 IgG의 1년 내구성Comment Published on 2021-08-012022-09-11 Journal: The Journal of Infection [Category] MERS, SARS, 진단, 치료기술, [키워드] Anti-S1 anti-Spike IgG antibodies baseline Baseline assessment coronavirus COVID-19 DiaSorin Durability IgG Loss Observational occurred Outpatient prospective observational study S1/S2 SARS-CoV-2 spike subject [DOI] 10.1016/j.jinf.2021.05.023 PMC 바로가기 [Article Type] Comment